Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. QNCX
QNCX logo

QNCX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Quince Therapeutics Inc (QNCX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.150
1 Day change
-1.71%
52 Week Range
45.500
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

QNCX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy, especially given the pre-market weakness and lack of strong catalyst support. The stock shows some short-term momentum improvement, but the broader technical setup is still bearish and there is no meaningful news, analyst upgrade, or insider/congress buying signal to justify an immediate long-term entry. My direct view: do not buy now; hold and wait for a clearer trend reversal or stronger catalyst.

Technical Analysis

Current price is 1.16 in pre-market, down 0.85%. Short-term momentum is mixed: MACD histogram is positive and expanding, which is constructive, but RSI_6 at 54.25 is neutral and does not indicate strong buying pressure. The moving average structure remains bearish with SMA_200 > SMA_20 > SMA_5, signaling the longer-term trend is still weak. Key levels to watch are pivot 1.085, resistance at 1.299 and 1.432, and support at 0.872 and 0.739. The stock trend model suggests only modest upside over the next week/month, which is not enough to overcome the bearish trend for a beginner long-term investor.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is not providing a meaningful bullish or bearish signal because the reported put-call ratios are 0.0 and there is no usable call/put volume detail. Historical volatility is high at 84.01, which implies the stock can move sharply, but with no clear options positioning edge, the options tape does not support an aggressive buy.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
11
Buy
1

Positive Catalysts

  • ["MACD histogram is above zero and expanding, suggesting improving short-term momentum.", "No recent negative news in the past week.", "No strong insider selling or hedge fund pressure is shown in the recent data.", "Stock trend model shows potential positive returns over the next week and month."]

Neutral/Negative Catalysts

  • ["Pre-market price is down 0.85%, showing weak immediate sentiment.", "No news in the recent week, so there is no event-driven catalyst.", "Bearish moving average structure suggests the broader trend remains weak.", "No AI Stock Picker signal today and no recent SwingMax signal.", "No recent congress trading data.", "Insiders and hedge funds are both neutral, with no significant trading trends.", "No financial snapshot was available, so there is no evidence of improving fundamentals."]

Financial Performance

No financial snapshot was available because of an error, so latest-quarter revenue, earnings, and growth trends cannot be assessed. Because the latest quarter season is not provided, there is no basis here to argue that fundamentals are improving.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible trend in Wall Street coverage. Based on the available information, the pros view is weak because there is no upgrade momentum or target increase, while the cons view is that the stock lacks catalyst support, has a bearish long-term chart structure, and does not have enough evidence of institutional conviction.

Wall Street analysts forecast QNCX stock price to rise
3 Analyst Rating
Wall Street analysts forecast QNCX stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.170
sliders
Low
5
Averages
7
High
10
Current: 1.170
sliders
Low
5
Averages
7
High
10
D. Boral Capital
Buy
to
Hold
downgrade
AI Analysis
2026-01-30
Reason
D. Boral Capital
Price Target
AI Analysis
2026-01-30
downgrade
Buy
to
Hold
Reason
D. Boral Capital downgraded Quince Therapeutics to Hold from Buy without a price target after the company reported negative results from its pivotal Phase 3 NEAT clinical trial in ataxia-telangiectasia. The company's core value driver has been removed, and the equity "appears fully impaired at this stage," the analyst tells investors in a research note.
Maxim
Buy
to
Hold
downgrade
2026-01-30
Reason
Maxim
Price Target
2026-01-30
downgrade
Buy
to
Hold
Reason
Maxim downgraded Quince Therapeutics to Hold from Buy.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for QNCX
Unlock Now

People Also Watch